JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $73
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has maintained a Market Outperform rating on Halozyme Therapeutics and raised its price target from $72 to $73.
November 01, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reaffirmed its positive outlook on Halozyme Therapeutics by maintaining a Market Outperform rating and slightly increasing the price target from $72 to $73.
The reaffirmation of a Market Outperform rating and a slight increase in the price target by JMP Securities suggests a positive outlook for Halozyme Therapeutics. This could lead to increased investor confidence and potentially a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100